|
Acute, often fatal disease caused by exotoxins produced by Clostridia
tetani. Characterised by generalized muscle rigidity, autonomic stability,
and sometimes convulsions.
Pathogenesis
tetanus only occurs when spores of C. tetani gain access into tissues
usual mode of entry is through puncture wound or laceration. Injury itself
is often trivial and in 20% of cases there is no evidence of wound
spores germinate from wound and toxin tetanospasmin is released into blood
stream. It is then taken up into motor nerve endings and transported into CNS
Clinical presentation
incubation period 2-60 days, but usually <15
period of onset (time from first symptom to first spasm) also variable
presenting symptoms pain and stiffness
subsequently develop rigidity. Initially this is localised (lockjaw) but
later becomes generalized
spasms are caused by external stimuli eg noise. As disease progresses even
minor stimuli may trigger severe spasms
laryngeal spasm may occur and is life threatening
Autonomic dysfunction
- occurs in severe cases
- begins a few days after muscle spasms (toxin has further to diffuse to reach
lateral horns of spinal cord)
- increased basal sympathetic tone: tachycardia, bowel and bladder dysfunction
- episodes of marked sympathetic overactivity involving both alpha and beta
receptors. Vascular resistance, CVP and CO (usually) are increased.
Manifestations include:
- labile hypertension
- pyrexia
- sweating
- pallor
- cyanosis of digits
- episodes usually of short duration. May occur without provocation
- due to reduced inhibition of post-synaptic sympathetic fibres in
intermediolateral cell column
- other postulated causes: loss of inhibition of adrenal medulla; direct
inhibition by tetanospasm of release of endogenous opiates; increased release of
thyroid hormone
- role of parasympathetic system unclear. Episodes of bradycardia, low TPR, low
CVP and profound hypotension are seen. Frequently pre-terminal. Sudden and
repeated cardiac arrests occur, especially in IV drug abusers. Have been
attributed to total withdrawal of sympathetic tone as atropine has no effect.
Alternative mechanisms: catecholamine-induced myocardial damage or direct
brainstem damage
Differential diagnosis
- dystonic reaction to tricyclics
- strychnine poisoning
- local temporomandibular diseae
- local oral disease
- convulsions
- tetany
- intracranial infections or haemorrhage
- psychiatric disorders
Management
Passive immunisation
- human antitetanus toxin: 3000-6000 U IV
- neutralizes only circulating toxin at best
- no prospective evidence of benefit
- meta-analysis suggests that intrathecal antitetanus toxin is ineffective and
suitable intrathecal preparations are not available
- adverse effects of antitetanus toxin include: fever, shivering, chest/back
pain, tachycardia and hypotension
- equine antitetanus serum can be used after testing and desensitization if
human antitoxin not available
Eradication of organism
- through cleaning of wound and extensive debridement of necrotic tissue
after antitoxin has been given
- antibiotics to destroy spores:
- metronidazole 500mg IV 8 hrly for 10 days. More effective than penicillin
- penicillin G 1-3 MU IV qds for 10 days. Penicillin is a central GABA
antagonist and may aggravate spasms
- erythromycin has been used but should not be routinely used
Suppression of effects of tetanospasmin
- ETT or tracheostomy if muscle spasms present
- ventilate if respiratory muscles involved
- muscle relaxants or deep sedation may be necessary to allow effective
ventilation
- deep sedation not only may prevent spasms but may improve autonomic
dysfunction
- traditionally combination of alpha and beta blockade used to treat sympathetic
overactivity
- alpha blockade: phenoxybenzamine, phentolamine, bethanidine or chlorpromazine
have been used
- unopposed beta blockade has resulted in death from acute CCF. Removal of beta
mediated vasodilatation in limb muscles causes a rise in SVR which beta blocked
myocardium may not be able to cope with
- esmolol can be used to control sympathetic crises but catecholamine levels
remain high with continuing risk of myocardial damage
- catecholamine output can be decreased with benzodiazepines and opiates. Former
increase affinity and efficacy of GABA while latter probably act by replacing
deficient endogenous opiates. Very large doses may be required and are well
tolerated
- magnesium has been used as an adjunct to sedation: aim for concentration of
2.5-4 mmol/L. Decreases SVR and HR with small decrease in CO. In animals
decreases catecholamine secretion and decreases receptor sensitivity. Has
additional advantage of neuromuscular blocking properties. Must be used with
sedatives and calcium supplements may be required
- clonidine has been used to produce sedation and control of autonomic
dysfunction
- intrathecal baclofen produces same result but causes significant respiratory
depression in 1/3
Complications
- hypoxia
- complications of mechanical ventilation
- myoglobinuria and attendant problems
- sepsis, particularly pneumonia
- fluid and electrolyte problems (including SIADH)
- DVT and PE
- bed sores
- fractures: especially of mid-thoracic vertebrae (no clinical importance: no
neurological complications, no pain and heal spontaneously without deformity)
Neonatal tetanus
- usually follows infection of the umbilical stump
- most often presents on day 7 of life with a short history of failure to feed
- spasms may be misdiagnosed as convulsions of another aetiology
- also vomiting (due to increased intra-abdominal pressure) and dehydration
(because of inability to swallow) often result in meningitis and sepsis being
considered first
Local tetanus
- uncommon mild form with mortality of 1%
- clinical features confined to a limb or muscle
- may be due to immunization
- Cephalic tetanus also rare. Results from injuries to head and neck, eye
infections or otitis media. Cranial nerves, especially VII commonly involved.
Prognosis poor. May progress to more generalized form.
Further reading
Lipman J, Oh TE. Tetanus. In Oh TE (ed), Intensive Care Manual, 4th ed. 1997
Butterworth Heinemann, Oxford, pp 423-7
http://www.cdc.gov/nip/publications/pink/tetanus.pdf
© Charles Gomersall November 1999
|